The plus sign (+) means "ADD" in programming and on calculator keyboards. For example, 10 + 7 means 10 added to 7. It is also used as a concatenation symbol for text fields. For example ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy ... the EC granted marketing authorization ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

Specifically, the FDA recently approved Arexvy, the world’s first vaccine to fight RSV in adults aged 60 and older. According to its manufacturer GSK, the single shot provides long-term ...

Pharmaceutical giant GSK has won a key part of the regulatory approval needed to roll out its vaccine for respiratory syncytial virus (RSV) to adults aged 50 to 59. The US Food and Drug ...

Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on Wednesday night. | Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

Soreness/redness/swelling/bruising at the injection site may occur. Muscle aches, joint pain, headache, or tiredness may also occur. If any of these effects last or ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...